Mediaboss Marketing

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram L, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:20949. https://doi.org/10.3322/caac.21660.

Article CAS PubMed Google Scholar

Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:72350. https://doi.org/10.1002/hep.29913.

Article PubMed Google Scholar

Villanueva A. Hepatocellular Carcinoma. N. Engl J Med. 2019;380:145062. https://doi.org/10.1056/NEJMra1713263.

Article CAS PubMed Google Scholar

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:215566. https://doi.org/10.1111/liv.12818.

Article PubMed PubMed Central Google Scholar

Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. J Fam Med Prim Care. 2021;10:355360. https://doi.org/10.4103/jfmpc.jfmpc_2347_20.

Article Google Scholar

Sidaway P. HAIC-FO improves outcomes in HCC. Nat Rev Clin Oncol. 2022;19:150. https://doi.org/10.1038/s41571-022-00599-0.

Article CAS PubMed Google Scholar

He M, Li Q, Zou R, Shen JX, Fang WQ, Tan GS, et al. Sorafenib plus hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5:95360. https://doi.org/10.1001/jamaoncol.2019.0250.

Article PubMed PubMed Central Google Scholar

Zhang Z, Li C, Liao W, Huang Y, Wang Z A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus. Cancers. 2022;14. https://doi.org/10.3390/cancers14153619.

Lencioni R, Llovet JM, Han G, Tak WY, Yang JM, Alfredo G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 2016;64:10908. https://doi.org/10.1016/j.jhep.2016.01.012.

Article CAS PubMed Google Scholar

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73:413. https://doi.org/10.1002/hep.31288.

Article CAS PubMed Google Scholar

An C, Zuo M, Li W, Chen Q, Wu P. Infiltrative Hepatocellular Carcinoma: Transcatheter arterial chemoembolization versus hepatic arterial infusion chemotherapy. Front Oncol. 2021;11:747496. https://doi.org/10.3389/fonc.2021.747496.

Article CAS PubMed PubMed Central Google Scholar

An C, Yao W, Zuo M, Li W, Chen Q, Wu P Pseudo-capsulated hepatocellular carcinoma: hepatic arterial infusion chemotherapy versus Transcatheter Arterial Chemoembolization. Acad Radiol. 2023. https://doi.org/10.1016/j.acra.2023.06.021.

Kourou K, Exarchos TP, Exarchos KP, Karamouzis MV, Fotiadis DI. Machine learning applications in cancer prognosis and prediction. Comput Struct Biotechnol J. 2015;13:817. https://doi.org/10.1016/j.csbj.2014.11.005.

Article CAS PubMed Google Scholar

An C, Yang H, Yu X, Han Z, Cheng Z, Liu F, et al. A machine learning model based on health records for predicting recurrence after microwave ablation of hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:67184. https://doi.org/10.2147/JHC.S358197.

Article PubMed PubMed Central Google Scholar

Uche-Anya E, Anyane-Yeboa A, Berzin TM, Ghassemi M, May FP. Artificial intelligence in gastroenterology and hepatology: how to advance clinical practice while ensuring health equity. Gut. 2022;71:190915. https://doi.org/10.1136/gutjnl-2021-326271.

Article PubMed Google Scholar

Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W173. https://doi.org/10.7326/M14-0698. Jan 6

Article PubMed Google Scholar

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019.

Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D. Society of Interventional Radiology Clinical Practice Guidelines. J Vasc Inter Radio. 2009;20:S189191. https://doi.org/10.1016/j.jvir.2009.04.035.

Article Google Scholar

Liu W, Wei R, Chen J, Li Y, Pang H, Zhang W, et al. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning. Eur Radiol. 2024 Jan 30. https://doi.org/10.1007/s00330-024-10581-2.

Article PubMed Google Scholar

Wang K, Tian J, Zheng C, Yang H, Ren J, Liu Y, et al. Interpretable prediction of 3-year all-cause mortality in patients with heart failure caused by coronary heart disease based on machine learning and SHAP. Comput Biol Med. 2021;137:104813. https://doi.org/10.1016/j.compbiomed.2021.104813.

Article PubMed Google Scholar

Ma M, Liu R, Wen C, Xu W, Xu Z, Wang S, et al. Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms. Eur Radiol. 2022;32:165262. https://doi.org/10.1007/s00330-021-08271-4.

Article CAS PubMed Google Scholar

Li QJ, He MK, Chen HW, Fang WQ, Zhou WM, Liu X, et al. Hepatic arterial infusion of Oxaliplatin, Fluorouracil, and Leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized Phase III trial. J Clin Oncol. 2022;40:15060. https://doi.org/10.1200/JCO.21.00608.

Article CAS PubMed Google Scholar

Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH, Yin GW, et al. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study. Eur Radiol. 2023. https://doi.org/10.1007/s00330-023-09754-2.

Johnson PJ, Berhane S, Kagebayashi C, Shinji S, Mabel T, Helen LR, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:5508. https://doi.org/10.1200/JCO.2014.57.9151.

Article PubMed Google Scholar

Reig M, Forner A, Rimola J, Joana F, Marta B, ngeles G, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:68193. https://doi.org/10.1016/j.jhep.2021.11.018.

Article PubMed Google Scholar

Song S, Bai M, Li X, Guo S, Yang W, Li C, et al. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma. Expert Rev Mol Diagn. 2022;22:36178. https://doi.org/10.1080/14737159.2022.2049248.

Article CAS PubMed Google Scholar

Hiraoka A, Ishimaru Y, Kawasaki H, Aibiki T, Okudaira T, Toshimori A, et al. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. Oncology. 2015;89:16774. https://doi.org/10.1159/000381808.

Article CAS PubMed Google Scholar

Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15:15560. https://doi.org/10.5582/bst.2021.01091.

Article CAS PubMed Google Scholar

Fan J, Tang ZY, Yu YQ, Wu ZQ, Ma ZC, Zhou XD, et al. Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg. 1998;15:6748. https://doi.org/10.1159/000018676.

Article CAS PubMed Google Scholar

Shi F, Lian S, Mai Q, Mo ZQ, Zhuang WH, Cui W, et al. Microwave ablation after downstaging of hepatocellular carcinoma: outcome was similar to tumor within Milan criteria. Eur Radiol. 2020;30:245462. https://doi.org/10.1007/s00330-019-06604-y.

Article PubMed Google Scholar

Binnewies M, Roberts EW, Kersten K, Vincent C, Douglas FF, Miriam M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:54150. https://doi.org/10.1038/s41591-018-0014-x.

Article CAS PubMed PubMed Central Google Scholar

Cao J, Su B, Peng R, Tang H, Tu DY, Tang YH, et al. Bioinformatics analysis of immune infiltrates and tripartite motif (TRIM) family genes in hepatocellular carcinoma. J Gastrointest Oncol. 2022;13:194258. https://doi.org/10.21037/jgo-22-619.

Article PubMed PubMed Central Google Scholar

Liu F, Liu D, Wang K, Xie XH, Su LY, Kuang M, et al. Deep learning radiomics based on contrast-enhanced ultrasound might optimize curative treatments for very-early or early-stage hepatocellular carcinoma patients. Liver Cancer. 2020;9:397413. https://doi.org/10.1159/000505694.

Article PubMed PubMed Central Google Scholar

Ding W, Wang Z, Liu FY, Cheng ZG, Yu XL, Han ZY, et al. A hybrid machine learning model based on semantic information can optimize treatment decision for nave single 3-5-cm HCC patients. Liver Cancer. 2022;11:25667. https://doi.org/10.1159/000522123.

Article CAS PubMed PubMed Central Google Scholar

See the rest here:
Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular ... - Nature.com